Key Highlights
- myBiometry raises $5M Seed funding led by Dexcom Ventures.
- Funding to accelerate fenoTRACK, a device for early detection of asthma and COPD exacerbations.
- fenoTRACK measures Type 2 airway inflammation via FeNO, empowering personalized patient care.
Source: Business Wire
Notable Quotes
- “Their data-driven sensing solution to address chronic diseases like asthma and COPD aligns with our mission to empower people to take control of their health.” — Jason Halac, Senior Director at Dexcom Ventures
- “We’re excited to partner with Dexcom Ventures and CareSource as we near the milestone of submitting fenoTRACK for regulatory clearance.” — Bryan Nolan, CEO at myBiometry
- “The impact of asthma and other lung diseases on the health and wellbeing of our members cannot be overstated.” — Steve Smitherman, Regional VP, Midwest at CareSource
SoHC's Take
This successful funding round marks a pivotal step for myBiometry in addressing a significant unmet need in chronic respiratory care. Asthma and COPD affect millions, with a substantial number of patients experiencing exacerbations that drive up healthcare costs and strain resources. With fenoTRACK, myBiometry offers a novel approach using FeNO data to monitor inflammation, giving clinicians a proactive tool to prevent exacerbations and personalize patient care. Dexcom Ventures’ involvement not only signals strong investor confidence but aligns with a broader trend in chronic disease management, emphasizing early intervention and patient empowerment through connected health solutions. This advancement by myBiometry holds the potential to transform outcomes and reduce the burden of respiratory diseases.
